OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab

OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for LusvertikimabDevelopment built on strong ...
Business Wire

OSE Immunotherapeutics and the FoRT Foundation Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non ...

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) and the FoRT Foundation (Fondazione Ricerca Traslazionale) announced today that the first patient has been randomized in the ...
Business Insider

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20 th Congress of ECCO NANTES, France – February 24, 2025, 7:30am CET - OSE ...
FierceBiotech

Ose narrows focus to conserve cash at expense of wider pipeline

Ose Immunotherapeutics is prioritizing its lung cancer med Tedopi and shifting the strategy for its ulcerative colitis (UC) therapy lusvertikimab as the French biotech maps out a financially ...
FierceBiotech

OSE, flying solo after Servier split, suggests symptom improvements for ulcerative colitis prospect

OSE Immunotherapeutics is hoping to show Servier what they walked away from. Around one year after the French drugmakers split up, the biotech has reported midphase data on an anti-IL-7 antibody ...